What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several year...
Asıl Yazarlar: | Testa, L, Bhindi, R, Van Gaal, W, Latini, R, Pizzocri, S, Lanotte, S, Biondi Zoccai, G, Valgimigli, M, Laudisa, M, Brambilla, N, Banning, A, Bedogni, F |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
2010
|
Benzer Materyaller
-
Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
Yazar:: Testa, L, ve diğerleri
Baskı/Yayın Bilgisi: (2010) -
Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
Yazar:: L. Testa, ve diğerleri
Baskı/Yayın Bilgisi: (2010-01-01) -
Use of prasugrel in patients with clopidogrel hypersensitivity
Yazar:: Aparna Joshi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01) -
Interaction between statins and clopidogrel: is there anything clinically relevant?
Yazar:: Bhindi, R, ve diğerleri
Baskı/Yayın Bilgisi: (2008) -
Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.
Yazar:: Testa, L, ve diğerleri
Baskı/Yayın Bilgisi: (2009)